---
title: "Vesugen Vascular Benefits, Study Dosage, Side Effects, Legal Status"
description: "Vesugen/KED guide: vascular benefits from studies, dosage from studies, side effects, FDA status, legal status, and Vezugen spelling."
canonical_url: "https://khavinsonatlas.com/peptides/vesugen.html"
last_updated: "2026-05-05"
---

# Vesugen / Vezugen / KED

Vesugen, also spelled Vezugen, is a synthetic tripeptide usually written KED, or Lys-Glu-Asp. KED is also embedded inside longer Khavinson sequences such as Prostamax KEDP, Livagen KEDA, Pancragen KEDW, and Testagen KEDG, so not every KED search result is about Vesugen.

## Evidence map

Vesugen/KED literature is mechanism-heavy and often Russian-language. Search clusters include vascular function, endothelial function, blood flow, microcirculation, atherosclerosis/restenosis mechanisms, and vascular aging.

## Benefits and study-only dosage

- 2015 vascular-culture paper: rat organotypic vascular cultures used vesugen at 0.05 ng/mL; dissociated rat aorta endothelial cultures used 20 ng/mL. These are rat in-vitro concentrations, not human dosage.
- 2016 KED abstract: reports endothelial mechanism markers such as endothelin-1 and sirtuin-1; accessible abstract does not state a human dose.
- 2013 Vezugen lower-limb insufficiency abstract: reports a course of Vezugen monotherapy in 41 post-surgery patients but does not state a dose; Russian-language abstract with limited accessible methods.

## Side effects

Side effects and contraindications cannot be inferred from the KED sequence alone. Cardiovascular contexts are high stakes; online peptide claims should not be used to change prescription drugs, anticoagulants, blood-pressure treatment, or clinician-directed care.

## FDA and legal status

This site does not identify an FDA-approved Vesugen/KED drug in the United States as of the May 5, 2026 review. FDA-approved status can be checked through Drugs@FDA and the Orange Book.

## Key sources

- PubMed KED atherosclerosis/restenosis abstract: https://pubmed.ncbi.nlm.nih.gov/28539025/
- PubMed Vezugen lower-limb insufficiency abstract: https://pubmed.ncbi.nlm.nih.gov/28976154/
- PubMed KED molecular-genetic review entry: https://pubmed.ncbi.nlm.nih.gov/34173097/

## Sitemap

See the full [markdown sitemap](/sitemap.md) for all pages.